MedImmune Gets Closer To Abbott With U.S. Bioscience Merger
Executive Summary
MedImmune's acquisition of U.S. Bioscience will likely lead to a tighter relationship with Abbott. Abbott already co-markets MedImmune's Synagis (palivizumab) and is in the process of acquiring Alza, which co-promotes U.S. Bioscience's top product Ethyol (amifostine) in the U.S.
You may also be interested in...
MedImmune To Add 38 Ethyol Reps Following Product Reacquisition
MedImmune will add 38 oncology reps to promote Ethyol (amifostine) following reacquisition of U.S. rights for the cytoprotective agent from Alza.
MedImmune To Add 38 Ethyol Reps Following Product Reacquisition
MedImmune will add 38 oncology reps to promote Ethyol (amifostine) following reacquisition of U.S. rights for the cytoprotective agent from Alza.
MedImmune Ethyol, Neutrexin sNDA Trials To Be Concluded In 2000
MedImmune expects to complete four Phase III trials in 2000 to gain additional indications for Ethyol and Neutrexin, Executive VP-R&D James Young, PhD, said at a biotechnology press briefing Jan. 6 in Gaithersburg, Md.